Campbell & CO Investment Adviser LLC Ligand Pharmaceuticals Inc Transaction History

Campbell & CO Investment Adviser LLC

$1.3 Billion
Q3 2024

A detailed history of Campbell & CO Investment Adviser LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Campbell & CO Investment Adviser LLC holds 3,690 shares of LGND stock, worth $451,434. This represents 0.03% of its overall portfolio holdings.

Number of Shares

3,690

Previous 3,690 -0.0%

Holding current value

$451,434

Previous $310,000 19.03%

% of portfolio

0.03%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$68.53 - $87.91 $73,395 - $94,151	-1,071 Reduced 22.5%	3,690 $310,000
Q1 2024 May 10, 2024	SELL	$68.64 - $89.2 $193,564 - $251,544	-2,820 Reduced 37.2%	4,761 $348,000
Q4 2023 Feb 13, 2024	BUY	$49.57 - $72.63 $120,702 - $176,854	2,435 Added 47.32%	7,581 $541,000
Q3 2023 Nov 08, 2023	BUY	$58.86 - $72.67 $36,375 - $44,910	618 Added 13.65%	5,146 $308,000
Q2 2023 Aug 11, 2023	BUY	$69.53 - $79.33 $10,499 - $11,978	151 Added 3.45%	4,528 $326,000
Q1 2023 May 11, 2023	SELL	$65.67 - $77.08 $52,338 - $61,432	-797 Reduced 15.4%	4,377 $321,000
Q4 2022 Feb 14, 2023	BUY	$61.72 - $96.74 $319,339 - $500,532	5,174 New	5,174 $345,000
Q1 2019 May 10, 2019	SELL	$105.93 - $142.47 $162,708 - $218,833	-1,536 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$128.36 - $272.13 $197,160 - $417,991	1,536 New	1,536 $231,000
Q2 2018 Jul 13, 2018	SELL	$150.77 - $207.98 $256,158 - $353,358	-1,699 Closed	0 $0
Q1 2018 May 04, 2018	BUY	$138.63 - $182.62 $235,532 - $310,271	1,699 New	1,699 $281,000

Others Institutions Holding LGND

# of Institutions

257

Shares Held

18.2M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.07B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

News

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.

Account

Campbell & CO Investment Adviser LLC Ligand Pharmaceuticals Inc Transaction History